Detailansicht

Wissensnetz

Person

Martin Dreyling (1961-)

Arzt

Name	Martin Dreyling
Zeit	1961- (Lebensdaten)
Ort	Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr. med.
Beruf	Arzt (charakteristischer Beruf)
Variante	M. Dreyling Martin Heinz Dreyling
Weitere Angaben	Seit 1998 an der Medizinischen Klinik III am Klinikum der Univ. München-Großhadern tätig; betreut seit 2002 als Oberarzt den Schwerpunkt Maligne Lymphome
Quelle	Internet
Datensatztyp	Person
GND-Nummer	134015819
Datensatz-ID	134015819
Beteiligt an alle anzeigen Conditional survival of younger patients with mantle cell lymphoma: results from a randomized phase III trial of the European MCL Network The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group Fast Facts: Follicular Lymphoma Follicular lymphoma Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis Maligne Lymphome Maligne Lymphome : Empfehlungen zur Diagnostik, Therapie und Nachsorge A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial The EHA Research Roadmap: Malignant Lymphoid Diseases Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report Schwere Candida-glabrata-Pankolitis und letale Aspergillus-fumigatus-Lungeninfektion vor dem Hintergrund einer Knochenmarkaplasie nach CD19-spezifischer CAR T-Zell-Therapie – ein Fallbericht A Phase II study to assess the safety and efficacy of the dual mTORC1/2 and PI3K inhibitor bimiralisib (PQR309) in relapsed, refractory lymphoma Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial Maligne Lymphome Maligne Lymphome : Empfehlungen zur Diagnostik, Therapie und Nachsorge Seltene Lymphome Zielgerichtete Therapie mit Ibrutinib bei B-Zell-Lymphomen : BTK-Hemmung: Schlüssel zur CLL-Primärtherapie? Das Mantelzell-Lymphom (MCL) Mantelzell-Lymphom : Informationen für Patienten Obinutuzumab (Gazyvaro) bei Patienten mit follikulärem Lymphom (FL) Ibrutinib : eine neue orale Therapieoption bei CLL und beim MCL Maligne Lymphome Maligne Lymphome : Empfehlungen zur Diagnostik, Therapie und Nachsorge MabThera SC : eine neue Darreichungsform zur Immuntherapie von Non-Hodgkin-Lymphomen Rare lymphomas Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial Maligne Lymphome A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms Temsirolimus : mTOR-Inhibition beim rezidivierten/refraktären Mantelzell-Lymphom Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network 2‐D PAGE‐based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma Indolente Non-Hodgkin-Lymphome Indolente Non-Hodgkin-Lymphome Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma Maligne Lymphome Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia Untersuchungen zur Gültigkeit indirekter klinischer Parameter des myokardialen Sauerstoff-Verbrauchs bei normaler und pathologischer Ventrikelfunktion

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Martin Dreyling (1961-)

Conditional survival of younger patients with mantle cell lymphoma: results from a randomized phase III trial of the European MCL Network

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network

Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group

Fast Facts: Follicular Lymphoma

Follicular lymphoma

Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up

Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis

Maligne Lymphome

Maligne Lymphome : Empfehlungen zur Diagnostik, Therapie und Nachsorge

A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial

The EHA Research Roadmap: Malignant Lymphoid Diseases

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report

Schwere Candida-glabrata-Pankolitis und letale Aspergillus-fumigatus-Lungeninfektion vor dem Hintergrund einer Knochenmarkaplasie nach CD19-spezifischer CAR T-Zell-Therapie – ein Fallbericht

A Phase II study to assess the safety and efficacy of the dual mTORC1/2 and PI3K inhibitor bimiralisib (PQR309) in relapsed, refractory lymphoma

Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study

Maligne Lymphome

Maligne Lymphome : Empfehlungen zur Diagnostik, Therapie und Nachsorge

Seltene Lymphome

Zielgerichtete Therapie mit Ibrutinib bei B-Zell-Lymphomen : BTK-Hemmung: Schlüssel zur CLL-Primärtherapie?

Das Mantelzell-Lymphom (MCL)

Mantelzell-Lymphom : Informationen für Patienten

Obinutuzumab (Gazyvaro) bei Patienten mit follikulärem Lymphom (FL)

Ibrutinib : eine neue orale Therapieoption bei CLL und beim MCL

Maligne Lymphome

Maligne Lymphome : Empfehlungen zur Diagnostik, Therapie und Nachsorge

MabThera SC : eine neue Darreichungsform zur Immuntherapie von Non-Hodgkin-Lymphomen

Rare lymphomas

Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial

Maligne Lymphome

A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms

Temsirolimus : mTOR-Inhibition beim rezidivierten/refraktären Mantelzell-Lymphom

Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network

2‐D PAGE‐based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma

Indolente Non-Hodgkin-Lymphome

Indolente Non-Hodgkin-Lymphome

Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma

Maligne Lymphome

Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia

Untersuchungen zur Gültigkeit indirekter klinischer Parameter des myokardialen Sauerstoff-Verbrauchs bei normaler und pathologischer Ventrikelfunktion